Neutralizing monoclonal antibodies for treatment of COVID-19

PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021‏ - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics

KP Martin, C Grimaldi, R Grempler, S Hansel, S Kumar - MAbs, 2023‏ - Taylor & Francis
There is considerable interest in the pharmaceutical industry toward development of
antibody-based biotherapeutics because they can selectively bind diverse receptors and …

Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

B Kelley, P De Moor, K Douglas, T Renshaw… - Current Opinion in …, 2022‏ - Elsevier
Highlights•Multiple companies are authorized to treat COVID-19 patients with monoclonal
antibodies (mAbs).•They were discovered, developed, manufactured, tested, and approved …

Stop** epidemics when and where they occur

E Torreele, M Kazatchkine, J Liu, M Dybul, M Cárdenas… - The Lancet, 2023‏ - thelancet.com
Democratic Republic of the Congo, and Central African Republic for many years, it was only
when the virus spread globally during 2022 that high-income countries focused on the …

Continuous multi‐column capture of monoclonal antibodies with convective diffusive membrane adsorbers

F Schmitz, E Knöchelmann, T Kruse… - Biotechnology and …, 2024‏ - Wiley Online Library
Downstream processing is the bottleneck in the continuous manufacturing of monoclonal
antibodies (mAbs). To overcome throughput limitations, two different continuous processes …

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs

T Qiu, L Zhang, Z Chen, Y Wang, T Mao… - Nucleic Acids …, 2023‏ - academic.oup.com
Identifying the exact epitope positions for a monoclonal antibody (mAb) is of critical
importance yet highly challenging to the Ab design of biomedical research. Based on …

[HTML][HTML] High mobility group box 1 (HMGB1): molecular signaling and potential therapeutic strategies

S Datta, MA Rahman, S Koka, KM Boini - Cells, 2024‏ - pmc.ncbi.nlm.nih.gov
High Mobility Group Box 1 (HMGB1) is a highly conserved non-histone chromatin-
associated protein across species, primarily recognized for its regulatory impact on vital …

High-throughput monoclonal antibody discovery from phage libraries: challenging the current preclinical pipeline to keep the pace with the increasing mAb demand

N Zambrano, G Froechlich, D Lazarevic, M Passariello… - Cancers, 2022‏ - mdpi.com
Simple Summary Monoclonal antibodies are increasingly used for a broad range of
diseases. Rising demand must face with time time-consuming and laborious processes to …

Stress factors in protein drug product manufacturing and their impact on product quality

TK Das, A Sreedhara, JD Colandene, DK Chou… - Journal of …, 2022‏ - Elsevier
Injectable protein-based medicinal products (drug products, or DPs) must be produced by
using sterile manufacturing processes to ensure product safety. In DP manufacturing the …

Upstream cell culture process characterization and in-process control strategy development at pandemic speed

J Xu, J Ou, KP McHugh, MC Borys, A Khetan - MAbs, 2022‏ - Taylor & Francis
As of early 2022, the coronavirus disease 2019 (COVID-19) pandemic remains a substantial
global health concern. Different treatments for COVID-19, such as anti-COVID-19 …